More Perfect Cure Rates for Achillion’s Six-Week Hep C Treatment

September 28, 2015 Achillion has released new data showing excellent results from six weeks of treatment with the company’s investigational hepatitis C virus (HCV) therapy odalasvir (ACH-3102) and Gilead Sciences’ Sovaldi (sofosbuvir). Achillion conducted a Phase II, open-label, randomized, partial-crossover study of six or eight weeks of the NS5A inhibitor…

Read More

Gilead’s All-Genotype Hep C Drug Boasts Excellent Cure Rates

September 23, 2015 Gilead Sciences appears poised to continue dominating the hepatitis C virus (HCV) treatment market as the company releases excellent results from several large studies of a new regimen that treats all genotypes of the virus. Gilead released top-line results from four international Phase III clinical trials, ASTRAL-1,…

Read More

New Liver Cancer Drug Gets FDA’s Fast-Track Designation

September 21, 2015 A new treatment for hepatocellular carcinoma (HCC, the most common form of liver cancer) has received a fast-track designation from the U.S. Food and Drug Administration (FDA), which will likely expedite its development. The FDA granted the designation to the Israeli biotech company Can-Fite BioPharma on behalf…

Read More

Hep C Treatment Viekira Pak Works Well in Real World

September 16, 2015 An ongoing real-world study of AbbVie’s hepatitis C virus (HCV) treatment Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), with or without ribavirin, has shown that the drug apparently works as well among those with genotype 1 of the virus as it did in clinical trials. Researchers from the AMBER trial…

Read More

Artificial Pancreas Works Well in Home Trial

Sept. 17, 2015 The latest trial of an artificial pancreas system offers good news for people with type 1 diabetes — the system lowered blood sugar levels without increasing the risk of dangerously low blood sugar (hypoglycemia), a new British study says. The testing, done at home by both adults…

Read More

Computer simulation of enzyme improves understanding of hepatitis C

11 September 2015 The scientists, from the International School of Advanced Studies (SISSA) in Trieste, Italy, describe their work in the journal Nucleic Acids Research. As scientists begin to understand more about how a particular virus replicates, the better the chances of finding drugs that stop the virus spreading. The…

Read More

Outreach invitations boost HCC screening in cirrhosis patients

15 September 2015 Dr. Amit G. Singal, hepatologist and associate professor of medicine at the University of Texas Southwestern Medical Center, and colleagues compared the clinical effectiveness of intervention strategies aimed at increasing one-time hepatocellular carcinoma (HCC) screening rates. Hepatocellular carcinoma is the second leading cause of cancer-related deaths worldwide.…

Read More

NASPGHAN, October 7-11, 2015 Annual Meeting & Postgraduate Course

Dear Colleagues: We invite you to attend “The NASPGHAN Annual Meeting and Postgraduate Course” to be held in Washington, D.C., from Thursday, October 7, 2015—Sunday, October 11, 2015 at the Washington Hilton Hotel. This year the meeting will be preceded by a Single Topic Symposium on Wednesday directed by Dr.…

Read More

Is the Hepatitis C Prevalence Estimate Too Low?

September 14, 2015 The current estimate that about 2.7 million Americans are chronically infected with hepatitis C virus (HCV) may exclude about 800,000 people. Publishing their findings in the journal Hepatology, researchers considered that the estimated hep C prevalence, based on 2003 to 2010 data from the National Health and…

Read More